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Early diagnosis of hepatocellular carcinoma (HCC) is the key to the delivery of effective therapies. The conventional serological
diagnostic test, estimation of serum alpha-fetoprotein (AFP) lacks both sensitivity and specificity as a screening tool and improved
tests are needed to complement ultrasound scanning, the major modality for surveillance of groups at high risk of HCC. We have
analysed the serum proteome of 182 patients with hepatitis C-induced liver cirrhosis (77 with HCC) by surface-enhanced laser
desorption/ionisation time-of-flight mass spectrometry (SELDI). The patients were split into a training set (84 non-HCC, 60 HCC)
and a ‘blind’ test set (21 non-HCC, 17 HCC). Neural networks developed on the training set were able to classify the blind test set
with 94% sensitivity (95% CI 73–99%) and 86% specificity (95% CI 65–95%). Two of the SELDI peaks (23/23.5kDa) were elevated
by an average of 50% in the serum of HCC patients (Po0.001) and were identified as k and l immunoglobulin light chains. This
approach may permit identification of several individual proteins, which, in combination, may offer a novel way to diagnose HCC.
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Hepatocellular carcinoma (HCC) is the fifth commonest cancer in
the world today and the overall 5-year survival rate remains less
than 5% (Parkin et al, 2001). Although the incidence rate is likely
to fall with the institution of mass vaccination against the hepatitis
B virus, initiated in the 1980s (Chang et al, 1997), this will not have
a major impact for many years as the age of presentation is over 50
years in most areas of the world. Furthermore, there is no prospect
of a vaccine against the hepatitis C virus, the major aetiological
factor for HCC in the US, Japan and Southern Europe (Di Bisceglie
et al, 1991; El-Sarag and Hashem, 2004). Despite the absence of
randomised clinical trials, there is strong evidence that surgical
resection, liver transplantation or ablative therapies significantly
improve survival (Bruix et al, 2001; Beaugrand et al, 2005). Such
approaches are, however, only applicable to those in whom the
tumour is detected at an early stage, typically less than 3cm in
diameter without vascular involvement and tumours only rarely
present with symptoms at this stage (Mazzaferro et al, 1996; Bruix
et al, 2001; Beaugrand et al, 2005). Early diagnosis has, therefore,
become a priority. Surveillance of high-risk groups, such as those
with cirrhosis, has been shown to permit detection of small
tumours and there is emerging evidence that this is associated with
improved survival (Sherman, 2005). Currently, surveillance
involves both serological testing with serum alpha-fetoprotein
(AFP) estimation and ultrasound scanning, typically at 6 monthly
intervals (Mazzaferro et al, 1996; Trevisani et al, 2002). However,
while AFP may be a useful diagnostic serum marker in patients
with advanced symptomatic disease, it is much less useful in
patients with earlier/small tumours where its sensitivity is low
(Mazzaferro et al, 1996; Johnson, 2001; Trevisani et al, 2002;
Sherman, 2005).
Ultrasound is far more sensitive (in the order of 80%) but it is
highly operator dependent (Trevisani et al, 2002; Sherman, 2005).
More specific and sensitive serological tests, to complement
ultrasound scanning, would be of great clinical value.
Surface-enhanced laser desorption/ionisation time-of-flight
mass spectrometry (SELDI) has shown potential for cancer
biomarker discovery (Adam et al, 2002; Li et al, 2002; Chen
et al, 2004; Zhang et al, 2004). A subset of the proteome of a
biological sample, such as serum, which binds to a specific solid-
phase chromatographic surface (known as a ‘protein-chip array’),
is subsequently ionised and detected by time-of-flight mass
spectrometry. The peak intensities in the SELDI spectra reflect
the abundance of proteins and peptides in the serum. The
technique is relatively high throughput, allowing samples to be
processed in 96-well format at a rate of up to several hundred
serum analyses per day per analyst. Various computer-based
pattern recognition approaches can then be applied to discrimi-
nate between patient groups, for example, those with and without a
particular cancer.
SELDI technology has been applied to identify potential
serological diagnostic markers for several cancers including
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sovarian cancer (Zhang et al, 2004), prostate cancer (Adam et al,
2002), breast cancer (Li et al, 2002) and colon cancer (Chen et al,
2004). Published studies have indicated that the SELDI approach
may also be used to diagnose HCC (Poon et al, 2003; Paradis
et al, 2005; Schwegler et al, 2005), although only Paradis et al
(2005) used an independent test set and gave details on
experimental reproducibility. All three studies were based on
small numbers of patients with either undefined or late-stage
HCC or chronic liver disease arising from several different
aetiologies. In addition, there has been little consensus on the
proteomic features that are significantly different in the serum of
HCC patients.
The present study was confined to patients with cirrhosis and
hepatitis C infection, as hepatitis C infection is the most common
cause of cirrhosis in the western world, carrying a high risk of
HCC. In addition, we chose to study patients with small HCC (3cm
mean diameter, range 1–11cm) in order to detect early changes
that could be usable in a screening situation. Being cognisant of
the controversies that surround the use of SELDI technology to
identify biomarkers (Baggerly et al, 2004; Diamandis, 2004;
Ransohoff, 2004), we were particularly careful to address issues
of reproducibility and validity. We used a ‘training’ data set to
develop artificial neural networks that permitted classification of
patients as HCC or non-HCC and then applied these networks to a
‘blind’ test data set. In addition, we purified and identified two of




Serum samples were collected between May 1994 and January 2005
at Jean Verdier Hospital, Bondy, France. Sample collection was
officially registered and all patients gave informed consent. Sera
were stored at  801C. All patients tested positive for hepatitis C
antibodies and hepatitis C RNA on the day of sampling.
Hepatocellular carcinoma was diagnosed histologically or non-
invasively, according to the Barcelona criteria (Bruix et al, 2001).
Samples were transported on dry ice to the University of
Birmingham, UK, for analysis in February 2005, defrosted (on
ice) and multiple 20ml aliquots taken and stored at  801C pending
SELDI analysis. Quality control (QC) samples were prepared by
mixing equal volumes of serum from 27 healthy individuals and
stored as multiple aliquots at  801C.
Study design
The study consisted of 84 non-HCC patients and 60 HCC patients
(the training set) and 38 samples where the classification of HCC/
non-HCC identities was not revealed to the UK-based proteomics
team (the blind test set) (Table 1). Independent duplicate SELDI
spectra were collected for all serum samples using Cu
2þ-loaded
IMAC30 protein-chip arrays. Samples were processed using six
96-well bioprocessors over a 2-week period. Three spots per
bioprocessor were devoted to identical QC samples, one spot to a
0–20kDa calibration mix and one spot to a 20–200kDa
calibration mix. Block randomisation was utilised: to the eight
spots on each protein-chip array, we applied in random sequence
three serum samples from patients without HCC, three serum
samples from patients with HCC and two serum samples from the
blind test set or one serum sample from the blind test set and
either one QC sample or calibration mix. All samples were
analysed once on bioprocessors 1–3 and then a separate aliquot of
each patient’s serum was analysed a second time on bioprocessors
4–6, ensuring that the measurement duplicates were not processed
on the same day.
Surface-enhanced laser desorption/ionisation procedure
An initial experiment using pooled sera from HCC and non-HCC
patients was conducted to decide whether H50, CM10, Q10 or
Cu
2þ-loaded IMAC30 protein-chip arrays were best able to detect
changes in the serum proteome characteristic of HCC. The Cu
2þ-
loaded IMAC30 performed best both in terms of the total number
of peaks detected and the number of peak intensities that were
significantly different between the HCC and non-HCC pooled
samples. We proceeded to analyse all of the patient’s samples in
duplicate using Cu
2þ-loaded IMAC30 protein-chip arrays. The
protein-chip arrays were placed in a 96-well bioprocessor and
prepared by a 5min incubation with 50ml of 100mM CuSO4
followed by a water rinse and 3 10min equilibrations with 200ml
of binding buffer (100mM NaCl, 500mM NaH2PO4/NaOH (pH
7.0)). Serum samples were defrosted on ice and diluted five-fold
with 9 M urea, 2% CHAPS, 50mM Tris/HCl (pH 9.0). Following a
brief vortex, the samples were left on ice for 30min prior to a 10-
fold dilution in binding buffer. These 50-fold final dilution samples
were loaded on the bioprocessor (100ml per spot) and incubated
at room temperature for 1h with shaking at 900r.p.m. After this
period, the nonbound material was discarded and the protein-chip
arrays were washed (4 10min incubations with 200ml of binding
buffer followed by a water rinse). The protein-chip arrays were
allowed to dry for 30min prior to addition of 1ml of 50% saturated
sinapinic acid in 50% acetonitrile, 0.5% trifluoroacetic acid. The
spots were then allowed to dry for another 30min prior to a second
1ml addition of sinapinic acid. The protein-chip arrays were
analysed in a PBS IIc protein chip reader equipped with an
autoloader (Ciphergen, UK). Spectra were collected over 0–20 and
0–200kDa ranges (488 laser shots) using laser intensities of 165
and 210, respectively. Spectra were externally calibrated in the 0–
20kDa range using all-in-one peptide standard (Ciphergen) with
added cytochrome c and myoglobin (Sigma). The 0–200kDa range
was calibrated using chymotrypsinogen, bovine serum albumin
and phosphorylase b (Sigma). Spectra were normalised using the
total ion current from 2 to 20 and 20 to 200kDa. Peaks were
selected and clustered using Biomarker Wizard software (Ciphergen)
with the signal to noise ratio 45 for the first pass and 42 for the
second, a cluster mass window of 0.2%, and a requirement for
peaks to be present in 420% of the spectra. The peak intensities
from the duplicate spectra from each patient were averaged and
the resulting peak intensities of the 60 HCC patients and 84 non-
HCC patients in the training set were compared by two-sample
t-test and the area under the receiver operator characteristic (ROC)
curve used to assess the discriminatory power of each peak.
Sample classification
Artificial neural networks (ANNs) were used to build committee
models to classify serum samples into HCC and non-HCC groups
using different numbers of significant peaks. The feed-forward
neural networks consisted of three layers: an input layer, a hidden
layer and an output layer. The number of input nodes was
determined by the number of significant peaks from which the
models were trained. The hidden layer connected the input and
Table 1 Patient demographics
Patient group No. patients Male/female Mean age (s.d.)
Non-HCC (training set) 84 44/40 65.4 (11.7)
HCC (training set) 60 41/19 71.8 (15.3)
Non-HCC (test set) 21 8/13 67.4 (12.2)
HCC (test set) 17 7/10 68.1 (10.0)
The table shows the number, sex and mean age of the patients analysed in this study.
HCC¼hepatocellular carcinoma.
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soutput layers, and the number of nodes in this layer controlled the
complexity and performance of the neural networks. The output
layer consisted of a single node whose output was used to classify
sample status, representing HCC or non-HCC. The ANN had full
connection from the input nodes to the hidden nodes and from the
hidden nodes to the output node. All of the connection weights
were randomly initialised in the range ( 1, þ1). The ANNs were
trained using the back propagation algorithm. In the procedure of
training a committee model, a 10-fold cross-validation approach
was used to reduce the risk of ‘over fit’ (Khan et al, 2001). The
training data set was randomly partitioned into 10 subvalidation
sets (10%) and 10 subtraining sets (90%). Each sample was
contained only once in the subvalidation sets. Thus, 10 different
ANNs were combined to create a committee model. A stepwise
approach was used in which many committee models were built
using various numbers of the most significant peaks. Significant
peaks were identified by two-sample t-test if P is less than 0.0123
(determined by a false discovery rate of 10%) (Benjamini and
Hochberg, 1995). The classification of the blind test set was made
according to the majority decision of the six best committee
models.
Biomarker purification and identification
Two pooled samples were prepared, one containing serum from
five HCC patients with high SELDI intensity at 23/23.5kDa and one
containing serum from five non-HCC patients with low SELDI
intensity at 23/23.5kDa. These two samples were diluted four-fold
with 9 M urea, 2% CHAPS, 50mM Tris/HCl (pH 9.0) and applied to
Q Ceramic HyperD F anion exchange resin. Proteins were eluted
stepwise from the resin using buffers at pH 9, 7, 5, 4, 3 and an
organic wash. The proteins in these fractions were monitored by
SELDI using Cu
2þ-loaded IMAC30 protein-chip arrays and the
fractions containing the 23/23.5kDa biomarkers were applied
to a monolithic C18 RP-HPLC column (BeckmanCoulter PF-2D
system) and eluted with an acetonitrile gradient in 0.1% tri-
fluoroacetic acid at a flow rate of 0.75mlmin
 1. Fractions were
collected (0.6min) and analysed by SELDI on Cu
2þ-loaded
IMAC30 protein-chip arrays. Fractions containing the 23/
23.5kDa peak were concentrated and further purified by non-
reducing 12% SDS–PAGE using MES running buffer (Invitrogen).
The bands corresponding to the 23/23.5kDa biomarkers were
excised and washed in 40mM ammonium bicarbonate/50%
acetonitrile. The gel slices were then treated with 50mM DTT in
40mM ammonium bicarbonate/10% acetonitrile (1h at 601C)
followed by 100mM iodoacetamide (30min at room temperature in
the dark). After several washes with 40mM ammonium bicarbo-
nate/10% acetonitrile, 20ml of 12.5mgml
 1 sequencing grade
trypsin (Promega) was added to the dried gel bands and digestion
allowed to proceed at 371C overnight. Peptides were extracted with
100ml of 3% formic acid and analysed by LC-MS/MS using a
ThermoFinnigan LCQ Deca XP Plus Ion-Trap linked directly to an
LC Packings/Dionex Ultimate nanobore HPLC system. MS/MS
data were searched against a database of nonredundant human
protein sequences extracted from NCBI using SEQUEST. Data were
filtered using Xcorr values of 1.5, 2 and 2.5 for singly, doubly and
triply charged parent ions, respectively, and only first hits were
considered.
RESULTS
Surface-enhanced laser desorption/ionisation quality
control
Quality control samples were run in triplicate on all six
bioprocessors. ANOVA analysis in Biomarker Wizard software
provided no evidence of significant differences between the QC
data from different bioprocessors. The coefficient of variation
(CV) of the 18 intensities measured for each proteomic feature was
calculated and averaged across the 35 most intense peaks. This
yielded an average CV of 2078% (mean7s.d.) obtained during
the course of the survey, consistent with the manufacturer’s
specification (15–20%). Visual inspection of the data revealed no
gross differences between duplicate spectra from each patient’s
serum samples and no data had to be discarded on this basis. An
example of duplicate 0–20 and 0–200kDa spectra for one HCC
patient is shown in Figure 1.
A number of patient’s samples were haemolysed giving rise to
atypical spectra. These were characterised by high haemoglobin
peaks (15.1 and 15.9kDa) and/or a low albumin peak (66.5kDa).
We discarded 34 samples from further data analysis on the basis
of a SELDI intensity 45 at 15.9kDa or o5 at 66.5kDa. The
haemolysed samples were distributed evenly among the HCC and
non-HCC patients.
Significant differences between the serum of HCC and non-
HCC patients
Of the 138 peaks picked and clustered by the Biomarker Wizard
software, 17 were significantly different at Po0.0123 (correspond-
ing to a false discovery rate of 10%) and these are shown in Table2.
These peaks have areas under the ROC curve ranging from 0.58 to
0.71 indicating possible diagnostic utility, especially if several of
these peaks could be used to build a classifier.
Artificial neural networks
A total of 17 ANN committee models were developed using up to



























































Figure 1 Duplicate low (0–20000m/z) and high (20000–200000m/z)
spectra from a single HCC patient. The spectra were collected 13 days
apart on different bioprocessors as described in the Materials and Methods
section.
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sbest performing committee models were selected by their ability to
correctly assign samples as HCC or non-HCC by 10-fold cross-
validation of the training set. A total of 170 ANNs were trained
(10 for each committee model). The committee models using the
most significant 4, 7, 10, 11, 15 and 17 features were selected with
average misclassification rates of 10–15% (cross-validation).
Rather than using individual committee models, the majority vote
from these six committee models was used to classify the blind
test set. It should be emphasised that the blind test set (the key
to which was held exclusively by the Bondy group) was only
unblinded when the classification model had been finalised, hence
operator bias can be excluded from the success of the ANN
classification.
The blind test set consisted of 17 HCC and 21 non-HCC patients.
The majority vote of our ANN committee models correctly
predicted 16 HCC patients and 18 non-HCC patients giving 94%
sensitivity (95% confidence interval 73–99%, calculated according
to Wilson, 1927) and 86% specificity (95% confidence interval 65–
95%). Interestingly, all 10 HCC patients in the blind test set that
had tumours less than 30mm were correctly identified, indicating
that SELDI can detect liver tumours at an early stage. One of the
non-HCC patients diagnosed as having HCC by our analytical
approach developed a 25mm diameter tumour within 6 months of
the sample being taken. The area under the ROC curve for the
ANN prediction of the blind test set was 0.92 (Figure 2) comparing
favourably with 0.73 for AFP (calculated across the whole study).
Biomarker identification
We selected a broad proteomic feature with peaks at m/z ratios of
22960 and 23530 (hereafter referred to as the ‘23/23.5kDa peak’)
that was significantly elevated in the serum of HCC patients
compared to those with cirrhosis alone as a suitable candidate for
purification and identification. Of the 138 SELDI peaks, these two
were the best discriminators for HCC in this cohort of patients
with the exception of a peak with an m/z ratio of 132200. Although
not formally identified, this peak copurifies with albumin and most
likely represents a dimer of albumin. The 23/23.5kDa peak was
purified in parallel from a pool of HCC sera with high intensity at
23/23.5kDa and a pool of non-HCC sera with low intensity at 23/
23.5kDa (Figure 3). These sera were denatured with urea at pH 9
and applied to anion exchange resin. A double peak at 23/23.5kDa
was found in the resin flow-through (‘pH 9 fraction’) from the
‘high’ sample but was less intense in the pH 9 fraction from the
‘low’ sample indicating that our biomarker is a basic protein that
does not bind to the resin under these conditions. The two pH 9
fractions, enriched in the 23/23.5kDa peak, were applied to an RP-
HPLC column and proteins eluted with an acetonitrile gradient.
The 23/23.5kDa peak was detected by SELDI in fractions
corresponding to 60–70% acetonitrile and again was more intense
in the ‘high’ sample (Figure 3). The fractions containing the 23/
23.5kDa peak were concentrated by centrifugal evaporation and
the proteins separated by SDS–PAGE (Figure 4). A band with
B23kDa mobility that was more intensely stained in the ‘high’
sample (Figure 4) was excised and trypsinised.
LC-MS/MS identified 34 tryptic peptides of immunoglobulin k
light chain and eight peptides from immunoglobulin l light chain.
Several homologous peptides, each with a unique mass but
reflecting the same part of the sequence of different k or l light
chains were seen. For example, 12 homologous peptides were
found corresponding to the N-terminal tryptic fragment of k light
chain. The data are summarised in Table 3. For each of the seven
sets of homologous peptides for the k light chain and five for the l
light chain, we have provided the sequence with the highest Xcorr.
The peptides listed in Table 3 cover 55 and 34% of the sequence of
k and l light chains, respectively, assuming a polypeptide length of
215 amino acids. The multiplicity of peptides demonstrates that
the 23/23.5kDa peak represents a diverse repertoire of immuno-
globulin light chains, consistent with both the broad elution from
the RP-HPLC column and the broad peak(s) in the SELDI spectra.
The identity of the 23/23.5kDa biomarker was confirmed using
an anti-human IgG polyclonal antibody to probe a blot of a
SDS–PAGE gel of samples with high and low intensities of the
biomarker (Figure 5). The anti-IgG antibody detects more
immunoglobulin protein with an electrophoretic mobility of
20–30kDa (light chains) in the serum samples with greater SELDI
intensity at 23/23.5kDa (Figure 4). The anti-IgG antibody also
showed increased binding to proteins of 50 and 100–200kDa in
Table 2 Proteomic features most significantly different between HCC
and non-HCC patients








 5 0.709 0.64
23530 5 10
 5 0.708 1.50
22960 0.0008 0.693 1.46
53830 0.0024 0.619 1.43
5254 0.0053 0.650 1.37
33350 0.0055 0.634 0.90
2362 0.0060 0.619 0.69
3088 0.0064 0.614 0.59
5811 0.0064 0.608 1.67
10270 0.0072 0.584 0.72
149410 0.0081 0.625 1.30
66480 0.0084 0.630 0.90
2273 0.0085 0.634 0.70
94710 0.0088 0.641 0.85
2792 0.0089 0.606 0.68
4795 0.0119 0.608 1.26
5826 0.0121 0.599 1.51
The table shows the 17 most significant proteomic features based on a two-sample t-
test. For each feature, we show the mass/charge (m/z) ratio, P-value, area under the
receiver operator characteristic (ROC) curve and the mean intensity in the HCC

























Figure 2 Receiver operator characteristic curve for the ANN
classificication of samples in the blind test set.
Serum proteomics of hepatocellular carcinoma
DG Ward et al
290




















sthe samples with greater SELDI intensity at 23/23.5kDa (data not
shown). This suggests that there is an overall increase in the level
of IgG in the serum of HCC patients. It is possible that the
SELDI peaks at 54 and 149kDa, upregulated in HCC patients
(Table 2), represent immunoglobulin heavy chains and intact IgG,
respectively.
DISCUSSION
In this study, we have shown that SELDI spectra are reproducible
and capable of detecting differences in the serum proteome
associated with HCC. Artificial neural networks developed using a
training set of 84 non-HCC and 60 HCC patients were able to
classify a blind test set of 21 non-HCC and 17 HCC patients with
94% sensitivity and 86% specificity. The accuracy of our ANN-
based classification is far higher than the currently accepted
biomarker, AFP (Gupta et al, 2003) (on the patient cohort used in
this study, AFP420ngml
 1 gave 46% sensitivity and 89%
specificity). However, this is only a phase 1 biomarker discovery
study (Pepe et al, 2001). Validation requires analysis of larger
cohorts of patients collected at multiple sites. Some early SELDI-
based biomarker studies have been heavily criticised for potential
bias in their design. This may arise from collection of the cancer
and noncancer sera in a different manner, differing storage
conditions or poor experimental design, for example, temporal
separation between the analysis of the cancer and noncancer
samples. In addition, the small sample numbers and high-
dimensionality of the data require that care is taken not to overfit
data. We have addressed these issues in our experimental design:
QC samples were run on all bioprocessors to exclude trends in the
protein-chip array reader’s performance, block randomisation
ensured that any variations in chip quality did not bias the study
between HCC and non-HCC or between training and validation
sets and the proteomic team in the UK that analysed the samples
were unaware of the identities of the blind test set: the ‘key’ was
held in France until the patient classification had been completed.
In addition, the patient groups were well matched with regard to
age (Table 1) and the male/female ratio was well balanced in the
test set. Although the male/female ratio was not as well balanced in
the training set, only two of the 17 peaks used to build ANNs were
significantly different between male and female patients (m/z 4795
and 66480, Po0.05). Therefore, we can be confident that the
proteomic changes we have identified are related to HCC. They
could be either proteins secreted by the tumour or arising from
secretion from the tumors, induced by inflammatory or immuno-
logical response to the tumour or the hallmark of predisposing
factors to HCC occurrence. The 23/23.5kDa peak that we have
identified as immunoglobulin light chains may fall into the latter
category: IgG levels are higher in patients with more advanced
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Figure 3 SELDI spectra following the 23/23.5kDa biomarker purifica-
tion. Pooled HCC and non-HCC sera, ‘high’ and ‘low’ in the biomarker,
respectively, were purified in parallel. Spectra for the original pooled sera,
the pH 9 fraction from the anion exchange separation and the peak fraction
from the RP-HPLC separation (fraction 25, 0.6min) are shown. *Indicates








































Figure 4 Coomassie stained 12% SDS–PAGE of fractions 24–27 (each
0.6min) of the RP-HPLC of pooled HCC sera high (H) and pooled non-
HCC sera low (L) in the 23/23.5kDa biomarker. Mwm¼molecular weight
markers. The rectangle encloses the band that provided the tryptic
peptides listed in Table 3.








EIVLTQSPATSLSPGER 4.37 12 Igk variable region
LLIYGASNLQTGVPSR 2.95 9 Igk variable region
FSGSNSGNTATLTISR 3.94 5 Igk variable region
TVAAPSVFIFPPSDEQLK 4.01 3 Igk constant region
SGTASVVCLLNNFYPR 4.79 1 Igk constant region
DSTYSLSSTLTLSK 3.67 1 Igk constant region
VYACEVTHQGLSSPVTKSFNRG 4.65 2 Igk constant region
YVLTQPPSVSVAPGQTAR 2.62 2 Igl variable region
SGTSASLAISGLR 3.91 1 Igl variable region
LTVLSQPK 2.52 3 Igl variable region
YAASSYLSLTPEQWK 2.95 1 Igl constant region





















Figure 5 Anti-human IgG blot. Proteins were separated by SDS–PAGE
on a 4–12% slab gel and blotted on to PVDF membrane. The blot was
probed using horseradish peroxidase-conjugated rabbit polyclonal anti-
human IgG antibody (Abcam). The blot shows alternating lanes of non-
HCC (N) and HCC (C) sera. The histogram shows the SELDI intensity of
each sample at m/z 22960.
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sPrevious reports have provided evidence that HCC produces
changes in the serum proteome of chronic liver disease patients
that can be detected by SELDI (Poon et al, 2003; Paradis et al, 2005;
Schwegler et al, 2005). Schwegler et al (2005) used SELDI to
analyse the serum of 50 hepatitis C patients (28 with HCC). They
achieved 61% sensitivity and 76% specificity (using decision trees)
and found peaks at 5.8 and 11.7kDa elevated in HCC. We also see a
peak at 5.8kDa that is upregulated in HCC. Paradis et al (2005)
were able to classify a set of 82 cirrhotic patients (38 with HCC)
with 90% accuracy using logistic regression of data from Zn
2þ-
loaded IMAC protein-chip arrays and published a list of 30
proteomic features significantly different between HCC and
non-HCC patients. Paradis et al did not observe our 23/23.5kDa
biomarker, but some discriminatory features are common to both
studies: the intensity of peaks at 33.2 and 66.4 and 102kDa are
decreased (66.4 and 33.2kDa presumably representing singly
and doubly charged ions of albumin). The use of Zn
2þ rather than
Cu
2þ as the chromatographic ligand and differences in sample
preparation and Protein-chip reader settings may account for
some differences between the studies in addition to different
underlying causes of chronic liver disease and stage of HCC
progression. The discriminatory peaks in this study also differ
from our earlier work in which serum samples were fractionated
prior to SELDI (Poon et al, 2003) and again this may be due to the
greater mean age and earlier stage of HCC progression in the
patients used in our current work. Additionally, the fractionation
may have unmasked better discriminators than those observed
with whole serum.
It is possible that the improved accuracy of immunoassays over
SELDI ‘quantitation’ could improve the performance of biomar-
kers originally identified by SELDI. The use of multiple carefully
chosen markers should enhance both the sensitivity and specificity
of HCC screening. Interestingly, unpublished pilot SELDI studies
in our laboratory using Cu
2þ-loaded IMAC30 protein-chip arrays
also indicate a 23/23.5kDa peak that is elevated by B20% in the
serum of colorectal cancer patients (with respect to healthy
controls), but not in the serum of oral, breast or prostate cancer
patients.
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